Amanote Research
Register
Sign In
Pcn251 - Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia in Europe, a Real-World Perspective
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.333
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
A. Martinez de Pinillos
P. Nasuti
C. Anger
I. Ricote
Publisher
Elsevier BV
Related search
Switches of Tyrosine-Kinase Inhibitors in Chronic Phase of Chronic Myeloid Leukemia in Real Life
American Journal of Hematology
Hematology
Stochastic Modelling of Tyrosine Kinase Inhibitor Rotation Therapy in Chronic Myeloid Leukaemia
BMC Cancer
Cancer Research
Oncology
Genetics
Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase
Revista de Chimie
Surfaces
Materials Science
Engineering
Materials Chemistry
Films
Coatings
Chemistry
Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia
Chemotherapy: Open Access
Cognitive Dysfunction After Withdrawal of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
American Journal of Hematology
Hematology
Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Preventing and Managing Cardiovascular Toxicities of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Cancer therapy & Oncology International Journal
Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
Turkish Journal of Haematology
Hematology
The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
Oncology
Hematology
